Prostate cancer (PC) is the third-leading cause of cancer-related deaths worldwide.
Although the current treatment strategies are progressing rapidly, PC is still representing a …

High mobility group box 1 (HMGB1) is an extremely versatile protein that is located
predominantly in the nucleus of quiescent eukaryotic cells, where it is critically involved in …

Background Drug resistance restrains the effect of drug therapy in non-small cell lung
cancer (NSCLC). However, the mechanism of the acquisition of drug resistance remains …

Background Diabetic kidney disease (DKD) is one of the most common chronic
complications of type 2 diabetes mellitus (T2DM), and it is particularly important to identify a …

Aims Bortezomib (BTZ) is described as the first-line agent for multiple myeloma (MM)
chemotherapy, but the emergence of BTZ resistance usually results in the failure of …

Early detection of prostate cancer (PC) is paramount as localized disease is generally
curable, while metastatic PC is generally incurable. There is a need for improved, minimally …

Radical prostatectomy is the gold standard treatment for prostate cancer (PCa); however, it
does not always completely cure PCa, and patients often experience a recurrence of the …

MicroRNAs (miRNAs) are small noncoding RNAs that function as epigenetic modulators
regulating almost any gene expression. Similarly, other noncoding RNAs, as well as …

Background Prostate cancer is one of the most common and socially significant cancers
among men. The aim of our study was to reveal changes in miRNA expression profiles …

Prostate cancer (PC) is one of the major male cancers. Differential diagnosis of PC is
indispensable for the individual therapy, ie, Gleason score (GS) that describes the grade of …